Clinical trial · Observational
Efficacy and Survival Analysis of Perioperative Treatment of Locally Advanced Gastric or Gastroesophageal Junction Cancer
Efficacy and Survival Prognosis Analysis of Perioperative Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260926-000001
Summary
Brief summary (as posted)
This study is a single-center, retrospective cohort study. The purpose is to evaluate different perioperative treatment options on the efficacy and survival prognosis of locally advanced GC/GEJC, clarify whether the tumor regression grade can influence survival of patients using neoadjuvant therapy. Moreover, we aim to explore the clinical and pathological characteristics that will affect the long-term survival benefit of patients who underwent perioperative treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemo only | Procedure | — | UNRESOLVED |
| Immunochemotherapy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- chemotherapy
- description
- patients who only used chemotherapy during neoadjuvant treatment
- interventionNames
- Procedure: Chemo only
- label
- immunochemotherapy
- description
- patients who used immunotherapy combined with chemotherapy during neoadjuvant treatment
- interventionNames
- Procedure: Immunochemotherapy
Primary outcomes (1)
- measure
- OS
- timeFrame
- From the start date of cycle 1 (each cycle is 14 days or 21 days) neoadjuvant therapy until the date of first documented death from any cause, assessed up to 100 months.
- description
- overall survival
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * (1) Pathologically diagnosed as gastric adenocarcinoma or esophageal-gastric junction adenocarcinoma, and has not received any anti-tumor treatment before (such as surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.) * (2) cT3-4N+M0 (according to AJCC version 8 stage) confirmed as resectable by CT or MRI. * (3) Patients who underwent adjuvant therapy before surgery. * (4) After neoadjuvant therapy , radical resection was performed at the Cancer Hospital of the Chinese Academy of Medical Sciences. * (5) Patients who have complete clinical, pathological and imaging data. Exclusion Criteria: * (1) It is known that peritoneal metastasis or peritoneal irrigation solution cytology is positive (CY1P0) or there is distant metastasis (according to the 8th edition of AJCC). * (2) There are unresectable factors, including irresectable tumor causes or surgical contraindications that are irresectable or refuse surgery. * (3) Those who have suffered from other malignant tumors within 5 years or at the same time, except for cured skin basal cell carcinoma and cervical cancer in situ and breast cancer in situ. * (4) Those who have had radiotherapy, interventional treatment and other local therapists before surgery. * (5) Patients whose key diagnosis and treatment information records were missing.
References
Publications (0)
Data not yet available